Brenus
Lyon, Auvergne-Rhône-Alpes, France · Biotechnology, Health Care, Therapeutics
Brenus is a Lyon-based biotech company focused on developing immunotherapy treatments for microsatellite-stable metastatic colorectal cancer (MSS mCRC). Its lead candidate, STC-1010, is an off-the-shelf cancer vaccine made from established colorectal cancer cell lines. The company aims to create a more effective immune response against colorectal tumors, which are often resistant to traditional th
Key facts
- Headquarters
- Lyon, Auvergne-Rhône-Alpes, France
- Employees
- 32
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- brenus.co
- Company page
Recent activity at Brenus
Brenus funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Series A | $11.0M |
Brenus in the news
- Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses. - BioSpace (Oct 23, 2026)
- Brenus Pharma Welcomes New European and Asia-Pacific Life Sciences Investors in Series A Extension - Business Wire (Jul 20, 2026)
- Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member - Business Wire (Jul 02, 2026)
- Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC) – News Hub - Medianet News Hub (May 27, 2026)
- Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC) - Business Wire (May 27, 2026)
- AACR 2025: Brenus Pharma Presents Late-breaking Preclinical Data on its “off-the-shelf” Next-generation Vaccine-based Immunotherapy Candidate, STC-1010, Now Moving to Clinic - BioSpace (May 07, 2025)
- AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer - Business Wire (Apr 14, 2026)
Companies similar to Brenus
- AIM ImmunoTech · Biotechnology, Health Care, Therapeutics
- Noema Pharma · Biotechnology, Health Care, Therapeutics
- STORM Therapeutics · Biotechnology, Health Care, Therapeutics
- ProteinQure · Biotechnology, Health Care, Therapeutics
- Orasis Pharmaceuticals · Biotechnology, Health Care, Therapeutics
About Brenus: questions and answers
What does Brenus do?
Brenus is a Lyon-based biotech company focused on developing immunotherapy treatments for microsatellite-stable metastatic colorectal cancer (MSS mCRC). Its lead candidate, STC-1010, is an off-the-shelf cancer vaccine made from established colorectal cancer cell lines. The company aims to create a more effective immune response against colorectal tumors, which are often resistant to traditional th
Where is Brenus headquartered?
Brenus is headquartered in Lyon, Auvergne-Rhône-Alpes, France.
How many employees does Brenus have?
Brenus has about 32 employees.
Has Brenus raised funding?
Yes. Fundz has recorded 1 funding event for Brenus. The most recent, Series A of $11.0M, was in Jul 2026.
What is the latest news on Brenus?
On Jul 21, 2026, Brenus secures €11M to advance colorectal cancer vaccine development in a Series A extension, increasing total funding to €33.2M. The investment includes participation from existing and new investors.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy